vs

Side-by-side financial comparison of Riley Exploration Permian, Inc. (REPX) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $97.3M, roughly 1.3× Riley Exploration Permian, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -5.3%). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -1.2%).

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

REPX vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.3× larger
ZLAB
$127.1M
$97.3M
REPX
Growing faster (revenue YoY)
ZLAB
ZLAB
+22.4% gap
ZLAB
17.1%
-5.3%
REPX
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-1.2%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
REPX
REPX
ZLAB
ZLAB
Revenue
$97.3M
$127.1M
Net Profit
Gross Margin
51.0%
Operating Margin
26.9%
-54.6%
Net Margin
Revenue YoY
-5.3%
17.1%
Net Profit YoY
EPS (diluted)
$4.02
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REPX
REPX
ZLAB
ZLAB
Q4 25
$97.3M
$127.1M
Q3 25
$106.9M
$115.4M
Q2 25
$85.4M
$109.1M
Q1 25
$102.5M
$105.7M
Q4 24
$102.7M
$108.5M
Q3 24
$102.3M
$101.8M
Q2 24
$105.4M
$100.1M
Q1 24
$99.7M
$87.1M
Net Profit
REPX
REPX
ZLAB
ZLAB
Q4 25
Q3 25
$16.3M
$-36.0M
Q2 25
$30.5M
$-40.7M
Q1 25
$28.6M
$-48.4M
Q4 24
Q3 24
$25.7M
$-41.7M
Q2 24
$33.5M
$-80.3M
Q1 24
$18.8M
$-53.5M
Gross Margin
REPX
REPX
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
REPX
REPX
ZLAB
ZLAB
Q4 25
26.9%
-54.6%
Q3 25
27.0%
-42.3%
Q2 25
33.7%
-50.3%
Q1 25
48.3%
-53.3%
Q4 24
31.2%
-62.6%
Q3 24
17.1%
-66.6%
Q2 24
50.9%
-76.0%
Q1 24
50.7%
-80.7%
Net Margin
REPX
REPX
ZLAB
ZLAB
Q4 25
Q3 25
15.3%
-31.2%
Q2 25
35.7%
-37.3%
Q1 25
27.9%
-45.8%
Q4 24
Q3 24
25.1%
-40.9%
Q2 24
31.8%
-80.2%
Q1 24
18.8%
-61.4%
EPS (diluted)
REPX
REPX
ZLAB
ZLAB
Q4 25
$4.02
$-0.05
Q3 25
$0.77
$-0.03
Q2 25
$1.44
$-0.04
Q1 25
$1.36
$-0.04
Q4 24
$0.52
$-0.09
Q3 24
$1.21
$-0.04
Q2 24
$1.59
$-0.08
Q1 24
$0.94
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REPX
REPX
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
$247.9M
Stockholders' EquityBook value
$634.2M
$715.5M
Total Assets
$1.2B
$1.2B
Debt / EquityLower = less leverage
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REPX
REPX
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Q1 24
$650.8M
Total Debt
REPX
REPX
ZLAB
ZLAB
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$288.6M
Q2 24
$322.7M
Q1 24
$341.8M
Stockholders' Equity
REPX
REPX
ZLAB
ZLAB
Q4 25
$634.2M
$715.5M
Q3 25
$566.5M
$759.9M
Q2 25
$556.9M
$791.7M
Q1 25
$532.4M
$810.8M
Q4 24
$510.6M
$840.9M
Q3 24
$507.4M
$667.7M
Q2 24
$489.0M
$704.2M
Q1 24
$434.6M
$762.2M
Total Assets
REPX
REPX
ZLAB
ZLAB
Q4 25
$1.2B
$1.2B
Q3 25
$1.2B
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$994.9M
$1.2B
Q4 24
$993.5M
$1.2B
Q3 24
$997.9M
$985.3M
Q2 24
$1.0B
$987.4M
Q1 24
$956.4M
$988.4M
Debt / Equity
REPX
REPX
ZLAB
ZLAB
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REPX
REPX
ZLAB
ZLAB
Operating Cash FlowLast quarter
$64.9M
$-26.0M
Free Cash FlowOCF − Capex
$-26.7M
FCF MarginFCF / Revenue
-21.0%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REPX
REPX
ZLAB
ZLAB
Q4 25
$64.9M
$-26.0M
Q3 25
$63.6M
$-32.0M
Q2 25
$33.6M
$-31.0M
Q1 25
$50.4M
$-61.7M
Q4 24
$66.4M
$-55.8M
Q3 24
$72.1M
$-26.8M
Q2 24
$51.6M
$-42.2M
Q1 24
$56.1M
$-90.1M
Free Cash Flow
REPX
REPX
ZLAB
ZLAB
Q4 25
$-26.7M
Q3 25
$-35.0M
Q2 25
$-33.9M
Q1 25
$-63.2M
Q4 24
$-58.4M
Q3 24
$-28.2M
Q2 24
$-42.9M
Q1 24
$-91.1M
FCF Margin
REPX
REPX
ZLAB
ZLAB
Q4 25
-21.0%
Q3 25
-30.4%
Q2 25
-31.1%
Q1 25
-59.9%
Q4 24
-53.8%
Q3 24
-27.7%
Q2 24
-42.9%
Q1 24
-104.5%
Capex Intensity
REPX
REPX
ZLAB
ZLAB
Q4 25
0.5%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
1.5%
Q4 24
2.4%
Q3 24
1.3%
Q2 24
0.7%
Q1 24
1.1%
Cash Conversion
REPX
REPX
ZLAB
ZLAB
Q4 25
Q3 25
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

REPX
REPX

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons